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Also the long-term safety of magnesium sulphate in 
both the mother and the baby has been documented 
9, 10
in the Magpie follow-up study . Therefore, on the 
basis of high-quality evidence, the World Health 
Organisat ion (WHO) has recommended 
magnesium sulphate as the most effective, safe and 
low-cost anticonvulsant drug for pre-eclampsia and 
11eclampsia .
Unfortunately despite the evidence, the drug has 
been listed as one of the 'new but underutilized 
technologies' especially in the developing countries 
12
where it is most needed . There are often 
systematic gaps between evidence of effectiveness 
and what is actually practiced. Why has it become so 
difficult in some countries to translate research 
findings into clinical practice? With respect to 
magnesium sulphate, a combination of factors have 
been identified and some of these factors shall be 
addressed in this discuss with particular reference to 
Nigeria. 
Ignorance, Apathy and System Failure: In many 
developing countries like Nigeria, continuing 
medical education and re-certification of health 
practitioners are neither mandatory nor obligatory. 
Hence, health workers practice their trade with 
whatever knowledge that was acquired at the 
training schools no matter how obsolete such might 
be. Few clinicians or policy makers in developing 
countries are aware of the concept of evidence-
13
based medicine . Secondly, the health care systems 
in many developing countries are not very efficient 
and research-led practice seems to be irrelevant 
14
when systems are in disarray . On the contrary, 
uptake of evidence-based, best practices is high in 
developed countries. For instance, a report in 2004 
on the management of eclampsia from Sweden 
shows the remarkably increased use of magnesium 
sulphate from 8% during 1980–1989 to 83% during 
151990–1999 . Even health workers that might have 
information on new products and technologies in 
Pre-eclampsia and eclampsia are hypertensive 
disorders of pregnancy that cause significant 
morbidity and mortality in the fetus and mother. The 
disorders account for about 9% of maternal deaths 
in Africa and Asia and about one-quarter of maternal 
1
deaths in Latin America and the Caribbean . In 
some parts of northern Nigeria for example, 
eclampsia alone contributes to almost one third of 
2, 3
maternal deaths .  The ultimate 'cure' for these 
disorders is delivery of the baby but there is a 
relationship between prognosis in eclampsia and the 
number of fits hence, the choice of anticonvulsant in 
patient care is very germane.
Modern management of pre-eclampsia and 
eclampsia could be said to have begun in 1925 with 
the report by Lazard on the use of magnesium 
4sulphate . While the use of magnesium sulphate 
went on to become the mainstay of treatment of pre-
eclampsia and eclampsia in the United States, drugs 
such as diazepam, phenytoin and 'lytic cocktail' 
became more widely used in the United Kingdom 
and her commonwealth allies. It was in 1995 that the 
superiority of magnesium sulphate became 
established. The Collaborative Eclampsia Trial 
compared the relative effectiveness of the three 
most popular treatments, viz., magnesium sulphate, 
5
diazepam and phenytoin . Women treated with 
magnesium sulphate were found to have a 52% and 
67% lower recurrence of convulsions than those 
treated with diazepam and phenytoin, respectively. 
Seven years later, in another multi-centre, 
randomized, study involving 33 countries and over 
10,000 patients with pre-eclampsia; magnesium 
sulphate was found to reduce the risk of eclampsia 
6and maternal deaths . Not only have maternal 
outcomes for pre-eclampsia and eclampsia after 
magnesium sulphate administration been studied, 
the perinatal outcomes have been assessed as well. 
Cochrane review articles reported much better 
outcomes for the babies, especially when 
magnesium sulphate was compared to diazepam 
7, 8
and phenytoin . 
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can be used to predict the presence or absence of 
toxicity without the need for serum magnesium 
estimates. Clinical monitors of deep tendon 
reflexes, respiratory rate and urinary output have 
been shown to be adequate in detecting presence or 
25
absence of toxicity . However, the concern for 
clinical monitoring especially with the deep tendon 
reflexes is the skill to perform the test at district and 
cottage hospital levels and the fact that in some 
patients with eclampsia the tendon reflexes are 
either absent, low or equivocal even before the 
commencement of any therapy.
Cost of Drug: One advantage of magnesium 
sulphate that has been constantly advertised is that it 
is a very cheap drug! This certainly is not the 
situation on the fields especially in many 
developing countries. The drug is not locally 
produced and it is thus scarce or relatively 
expensive when compared with 'rival' drugs like 
diazepam. Cost is still a major problem in Nigeria 
despite efforts by a pharmaceutical company to 
import and distribute the drug. Unless the drug is 
subsidized or provided free to patients with pre-
eclampsia and eclampsia, the uptake would remain 
low as most of such patients are impoverished. It has 
also been argued that because of the limited scope of 
parenteral magnesium sulphate usage it would need 
support. Yet there is a group that thinks the drug is 
too cheap to motivate mass manufacturing, 
26licensing, production and distribution . In 
Mozambique and Zimbabwe, failure in registration, 
procurement and distribution mechanisms is said to 
27
contribute to its poor availability . 
Pre-Eclampsia or Eclampsia: The tendency is for 
patients with pre-eclampsia to decline admission for 
in-patient care because of the apparent lack of 
symptoms until the situation deteriorates to full 
blown eclampsia. Thus we are likely to see more 
patients with eclampsia on magnesium sulphate 
than those with pre-eclampsia. Another significant 
barrier to improving care of women with 
preeclampsia and eclampsia is the fact that fewer 
than 60% of women in some countries have access 
to services where pre-eclampsia could likely be 
diagnosed, and fewer than 40% have access to 
professionals who could administer magnesium 
sulphate. A very significant portion of the maternal 
deaths from eclampsia reported from many 
developing countries are among women who had 
multiple seizures outside the hospital and those 
some developing countries are not compelled by 
regulatory bodies to implement best practices. To 
address the problem of ignorance, organization of 
seminars and workshops has been proposed but that 
alone does not work as demonstrated from the report 
from Mexico and Thailand. The authors concluded 
that knowledge access is essential but probably not 
sufficient to lead to changes in health care practices 
16. Therefore, there must be facilitative supervision 
by the appropriate authorities and regulatory bodies 
with appropriate sanctions where necessary to 
overcome the problem of underutilizing new and 
effective products and technologies. 
Dosage: There are two standard protocols for using 
magnesium sulphate as an anticonvulsant in pre-
eclampsia and eclampsia. In both regimens, 
initiation is by the intravenous route, the difference 
is in the route of the maintenance doses. With the 
Zuspan regimen, an initial intravenous bolus dose 
of 4gm is given slowly over a period of 5-10 minutes 
and maintenance is with 1-2gm hourly by 
intravenous infusion for 24 hours using an infusion 
17
pump .  But in the absence of infusion pumps, 
which is not uncommon in the developing countries, 
gravity–fed drip sets can be used with reliance on 
the duty staff to monitor and control the rate of 
18infusion . In the Pritchard regimen, initiation is 
also with 4gm bolus  intravenously over 5-10 
minutes and an additional 10gm intramuscularly 
(5gm each buttock).  This is then followed by 5gm 
intramuscularly at 4 hourly intervals into alternate 
19buttocks for 24 hours . Some consider these 
regimens excessive and labour intensive, hence the 
20
call to research on shorter courses . This has led to 
an avalanche of shorter and lower dosing protocols 
21, 22, 23
 with small sample sizes and/or less than 
rigorous methods. Perhaps, what is needed now is a 
well coordinated, large, multi-centre, randomized 
trial to validate these short regimens. Next, is 
whether or not other routes of administration of 
magnesium sulphate would be effective especially 
for use by health workers at the primary health care 
level?
Fear of Toxicity: The greatest concern with the use 
of magnesium sulphate has been that of toxicity.  
But the initial assumption that magnesium sulphate 
has a narrow therapeutic index has been disproved 
24. There is reasonable margin between the 
therapeutic levels and levels that would cause 
toxicity. There are established clinical monitors that 
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without antenatal care . Improvements in 
facility-based care including the provision of 
magnesium sulphate are not likely to affect these 
women or prevent their deaths.
CONCLUSION
The necessary research to identify the best anti-
convulsant drug for the treatment of severe pre-
eclampsia and eclampsia has been concluded and 
the results are clear. Magnesium sulphate is safe, 
effective and is now available for use. Some 
countries have achieved success in changing both 
their policies and practices to incorporate this new 
knowledge. In Nigeria, most of the obstacles to 
usage are surmountable. Clinical practices should 
be audited to ensure best practices. But in the 
absence of 'auditors', the immediate challenge to us 
as clinicians and nurse/midwives is to ensure that 
we use magnesium sulphate in our practice and 
preach it to those that do not know so that 
collectively we can give our patients best practices 
despite the dysfunctional system. Scaling up 
magnesium sulphate for treatment of eclampsia and 
severe pre-eclampsia will significantly advance the 
safe motherhood agenda and contribute to attaining 
30the Millennium Development Goals by 2015 . Yes, 
we can!
REFERENCES
1. Khan KS, Wojdyla D, Say L, Gulmezoglu 
AM, Van Look PF. WHO analysis of causes 
of maternal death: a systematic review. 
Lancet 2006; 367: 1066-74.
2. Audu LR, Ekele BA. A ten year review of 
maternal mortality in Sokoto, Northern 
Nigeria. West Afr J Med 2002; 21: 74 – 76.
3. El-Nafaty AU, Melah GS., Massa AH, Audu 
BM, Nelda M. The analysis of eclamptic 
morbidity and mortality in Specialist 
Hospital Gombe, Nigeria. Journal of 
Obstetrics and Gynaecology 2000; 24(2): 
142–147.
4. Lazard, E.M. 1925. A preliminary report on 
the intravenous use of magnesium sulfate in 
puerperal eclampsia. Am J Obstet Gynecol 
9(XX):178–188.
5. Eclampsia Trial Collaborative Group. 
Which anticonvulsant for women with 
e c l a m p s i a ?  E v i d e n c e  f r o m  t h e  
Collaborative Eclampsia Trial. Lancet, 
1995; 345: 1455 – 1463.
35
Trop J Obstet Gynaecol, Vol 27 (1), April 2010
24. Lu JF, Nightingale CH.  Magnesium 
sulphate in eclampsia and pre-eclampsia: 
pharmacokinetic principles. Clinical 
pharmacokinetics 2000; 38(4): 305 – 314.
25. Ekele BA, Badung SLH. Is serum 
magnesium estimate necessary in patients 
with eclampsia on magnesium sulphate?  
Afr J Reprod Health 2005; 9(1): 128 – 132.
26. Lumbiganon P, Gulmezoglu AM, Piaggio G, 
Langer M, Grimshaw J. Magnesium sulfate 
is not used for pre-eclampsia and eclampsia 
in Mexico and Thailand as much as it should 
be. Bull World Health Organ 2007; 85(10): 
763-7.
27. Sevene E, Lewin S, Mariano A, Woelk G, 
Oxman AD, Matinhure S, et al. System and 
market failures: the unavailability of 
magnesium sulphate for the treatment of 
e c l a m p s i a  a n d  p r e - e c l a m p s i a  i n  
Mozambique and Zimbabwe. BMJ 2005; 
331(7519): 765-769.
28. Sibai BM. Diagnosis, prevention, and 
management of eclampsia. Am J Obstet 
Gynecol 2005; 105(2):402–410.
29. Katz  VL,  Farmer  R,  Kul ler  JA.  
Preeclampsia into eclampsia: toward a new 
paradigm. Am J Obstet Gynecol 2000; 
182(6):1389–1396.
Langer A, Villar J, Tell K, Kim T, Kennedy S. 
Reducing eclampsia related deaths-a clarion call 
to action. Lancet 2008; 371: 705-6.
Lumbiganon P, Villar J, Grimshaw J. Cluster 
randomized trial of an active, multifaceted 
educational intervention based on the WHO 
Reproductive Health Library to improve 
obs te t r i c  p rac t ices .  BJOG  2007;  
114(1):16–23.
17. Zuspan SP. Problems encountered in the 
t r ea tmen t  o f  p regnancy  induced  
hypertension. Am J Obstet Gynecol 1978; 
131: 591 – 597.
18. Adewole IF, Oladokun A, Okewole AI, 
Omigbodun AO, Afolabi A, Ekele BA et al.  
Magnesium sulphate for treatment of 
eclampsia:  the Nigerian experience.  Afr J 
Med med Sci, 2000; 29: 239 – 241.
19. Pritchard JA, Cunningham FG, Pritchard 
SA. The Parkland Memorial Hospital 
protocol for treatment of eclampsia: 
evaluation of 245 cases. Am J Obstet 
Gynecol 1984; 148: 951– 963.
20. Weeks, A.D. and Ononge, S. 2002. The 
Magpie Trial. Lancet 360(9342):1331.
21. Begum R, Begum A, Johanson R, Ali MN, 
Akhter S. A low dose (Dhaka) magnesium 
sulphate regime for eclampsia. Acta Obstet 
Gynecol Scand 2001; 80 (11): 998-1002.
22. Shilva, Saha SC, Kalra J, Prasad R. Safety 
and efficacy of low-dose MgSO4 in the 
treatment of eclampsia. Int J Gynaecol 
Obstet 2007; 97: 150-1.
23. Ekele BA, Ahmed Y. Magnesium sulphate 
for eclampsia. Int J Gynecol Obstet 2004; 
87: 149 – 150
